Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Doses of IDEC-Y2B8 (Zevalin) in Relapsed NHL
NCT00012298Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2001
- Primary completion
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in follicular lymphoma (FL), non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Started Apr 2001; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00012298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012298.